nice
After-Hours Stock Movers: Apple, Qualcomm, Skyworks Solutions and more
$Regulus Therapeutics Inc$. 25% LOWER; announced the prioritization of its promising, next-generation candidate, RGLS8429, for the treatment of Autosomal Dominant Polycystic Kidney Disease . The Company recently completed the dosing period of the in-life portion of the IND-enabling toxicity studies for RGLS8429; anticipates submitting an Investigational New Drug application ; and subject to U.S. Food and Drug Administration clearance, initiating a phase 1 study in the second quarter of 2022.$N
免责声明:上述内容仅代表发帖人个人观点,不构成本平台的任何投资建议。
4
举报
登录后可参与评论
![empty](https://c1.itigergrowtha.com/community/assets/media/empty-default.06ba11e0.png)
暂无评论